T. Ohune et al., PHASE-I STUDY AND CLINICAL PHARMACOLOGICAL EVALUATION OF DAILY ORAL ETOPOSIDE COMBINED WITH CARBOPLATIN IN PATIENTS WITH LUNG-CANCER, Japanese journal of cancer research, 86(5), 1995, pp. 490-500
Twenty-eight patients with inoperable or relapsed lung cancer were giv
en a combination of oral etoposide, administered once a day at doses r
anging from 40 to 60 mg/m(2)/day (d) for 21 consecutive days, and carb
oplatin, administered intravenously over 1 h at doses ranging from 300
to 400 mg/m(2) on day 1 to determine the appropriate doses of this co
mbination. In addition, pharmacokinetic and pharmacodynamic analyses w
ere performed. All the patients had a performance status of 0 to 1. Se
rum etoposide and free platinum (Pt) concentrations were measured usin
g high-performance liquid chromatography and atomic absorption, respec
tively. Myelosuppression, nausea and vomiting were the dose-limiting t
oxicities of this schedule. The maximum tolerated dose (MTD) was 50 mg
/m(2)/d oral etoposide for 21 days and 400 mg/m(2) i.v. carboplatin on
day 1. For heavily pretreated patients, the MTD was 40 mg/m(2)/d oral
etoposide for 21 days and 350 mg/m(2) i.v. carboplatin on day 1. No c
umulative increase in the area under the concentration-time curve (AUG
) for oral etoposide over time was observed. There were significant co
rrelations between the free Pt serum level (6, 8, 12, 24 h post dose)
and etoposide AUC level (days 1, 10 and 21) for graded hematological t
oxicity, and the percentage decreases and nadir counts of hemoglobin,
leukocytes, neutrophils and platelets. Several pharmacodynamic models
were developed to predict the hematological toxicity. In order to faci
litate pharmacodynamic evaluations in future studies, a limited sampli
ng model for oral etoposide was also developed and validated.